These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 33258798)

  • 1. Looking for new anabolic treatment from rare diseases of bone formation.
    Rossi M; Battafarano G; De Martino V; Scillitani A; Minisola S; Del Fattore A
    J Endocrinol; 2021 Feb; 248(2):R29-R40. PubMed ID: 33258798
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sclerostin: current knowledge and future perspectives.
    Moester MJ; Papapoulos SE; Löwik CW; van Bezooijen RL
    Calcif Tissue Int; 2010 Aug; 87(2):99-107. PubMed ID: 20473488
    [TBL] [Abstract][Full Text] [Related]  

  • 3. From disease to treatment: from rare skeletal disorders to treatments for osteoporosis.
    Appelman-Dijkstra NM; Papapoulos SE
    Endocrine; 2016 Jun; 52(3):414-26. PubMed ID: 26892377
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting sclerostin as potential treatment of osteoporosis.
    Papapoulos SE
    Ann Rheum Dis; 2011 Mar; 70 Suppl 1():i119-22. PubMed ID: 21339215
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Lrp4R1170Q Homozygous Knock-In Mouse Recapitulates the Bone Phenotype of Sclerosteosis in Humans.
    Boudin E; Yorgan T; Fijalkowski I; Sonntag S; Steenackers E; Hendrickx G; Peeters S; De Maré A; Vervaet B; Verhulst A; Mortier G; D'Haese P; Schinke T; Van Hul W
    J Bone Miner Res; 2017 Aug; 32(8):1739-1749. PubMed ID: 28477420
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetics of Sost/SOST in sclerosteosis and van Buchem disease animal models.
    Sebastian A; Loots GG
    Metabolism; 2018 Mar; 80():38-47. PubMed ID: 29080811
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of Compound Heterozygous Variants in LRP4 Demonstrates That a Pathogenic Variant outside the Third β-Propeller Domain Can Cause Sclerosteosis.
    Huybrechts Y; Boudin E; Hendrickx G; Steenackers E; Hamdy N; Mortier G; Martínez Díaz-Guerra G; Bracamonte MS; Appelman-Dijkstra NM; Van Hul W
    Genes (Basel); 2021 Dec; 13(1):. PubMed ID: 35052419
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Functional characterization of osteoblasts and osteoclasts from alkaline phosphatase knockout mice.
    Wennberg C; Hessle L; Lundberg P; Mauro S; Narisawa S; Lerner UH; Millán JL
    J Bone Miner Res; 2000 Oct; 15(10):1879-88. PubMed ID: 11028439
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Miscellaneous Bone Disorders.
    Mughal MZ; Padidela R
    Endocr Dev; 2015; 28():226-246. PubMed ID: 26138845
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sclerostin: recent advances and clinical implications.
    Honasoge M; Rao AD; Rao SD
    Curr Opin Endocrinol Diabetes Obes; 2014 Dec; 21(6):437-46. PubMed ID: 25333305
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bone-targeted replacement therapy for hypophosphatasia.
    Drake MT; Khosla S
    J Bone Miner Res; 2008 Jun; 23(6):775-6. PubMed ID: 18318644
    [No Abstract]   [Full Text] [Related]  

  • 12. Sclerostin deficiency in humans.
    van Lierop AH; Appelman-Dijkstra NM; Papapoulos SE
    Bone; 2017 Mar; 96():51-62. PubMed ID: 27742500
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The sclerostin story: from human genetics to the development of novel anabolic treatment for osteoporosis.
    Yavropoulou MP; Xygonakis C; Lolou M; Karadimou F; Yovos JG
    Hormones (Athens); 2014; 13(4):323-37. PubMed ID: 25555179
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sclerosing bone disorders.
    de Vernejoul MC
    Best Pract Res Clin Rheumatol; 2008 Mar; 22(1):71-83. PubMed ID: 18328982
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Osteocyte as the New Discovery of Therapeutic Options in Rare Bone Diseases.
    Pathak JL; Bravenboer N; Klein-Nulend J
    Front Endocrinol (Lausanne); 2020; 11():405. PubMed ID: 32733380
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sclerostin: how human mutations have helped reveal a new target for the treatment of osteoporosis.
    Robinson MK; Caminis J; Brunkow ME
    Drug Discov Today; 2013 Jul; 18(13-14):637-43. PubMed ID: 23579167
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Camurati-Engelmann disease (progressive diaphyseal dysplasia). Differential diagnostic problems].
    Mastragelopulos N; Bähr R; Pfister U
    Unfallchirurgie; 1989 Apr; 15(2):104-7. PubMed ID: 2734958
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biochemical markers of bone turnover in Camurati-Engelmann disease: a report on four cases in one family.
    Hernández MV; Peris P; Guañabens N; Alvarez L; Monegal A; Pons F; Ponce A; Muñoz-Gómez J
    Calcif Tissue Int; 1997 Jul; 61(1):48-51. PubMed ID: 9192513
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Novel Domain-Specific Mutation in a Sclerosteosis Patient Suggests a Role of LRP4 as an Anchor for Sclerostin in Human Bone.
    Fijalkowski I; Geets E; Steenackers E; Van Hoof V; Ramos FJ; Mortier G; Fortuna AM; Van Hul W; Boudin E
    J Bone Miner Res; 2016 Apr; 31(4):874-81. PubMed ID: 26751728
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A new LRP6 variant and Camurati-Engelmann-like disease.
    Pickering ME; Ltaief-Boudrigua A; Feurer E; Collet C; Chapurlat R
    Bone; 2021 Feb; 143():115706. PubMed ID: 33164853
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.